Irinotecan plus fluorouracil-based regimen as second or third-line chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma

Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial

(2014) Susan J Dutton et al.   LANCET ONCOLOGY

S-1 Monotherapy as Second- or Third-Line Chemotherapy for Unresectable and Recurrent Esophageal Squamous Cell Carcinoma

(2013) Yasunori Akutsu et al.   ONCOLOGY

A phase II study of biweekly paclitaxel and cisplatin chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma: ERCC1 expression predicts response to chemotherapy

(2012) Jing Huang et al.   MEDICAL ONCOLOGY

Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer

(2011) Eliza Hawkes et al.   EUROPEAN JOURNAL OF CANCER

Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum

(2011) Katrine R. Schoennemann et al.   Gastric Cancer

Second-Line Combination Chemotherapy with Docetaxel and Nedaplatin for Cisplatin-Pretreated Refractory Metastatic/Recurrent Esophageal Squamous Cell Carcinoma

(2010) Jianhua Jin et al.   Journal of Thoracic Oncology

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

(2010) Kei Muro et al.   LANCET ONCOLOGY

A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy

(2008) Alexandra Leary et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY